Robert W. Duggan

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Clearwater, FL
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Robert W. Duggan
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert W. Duggan

Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
25,824,474
Estimated value
$489,632,027
Report date
12 Jun 2026
Price
$18.96
Ownership
By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
10,199,776
Estimated value
$193,387,752
Report date
12 Jun 2026
Price
$18.96
Ownership
By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
9,590,558
Estimated value
$110,051,658
Report date
29 Apr 2025
Price
$9.18
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
11,988,198
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Common Stock
Shares / value
76,680
Estimated value
$1,453,852
Report date
12 Jun 2026
Price
$18.96
Ownership
Immediate family member of Spouse
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
11,232
Estimated value
$98,392
Report date
02 Jan 2026
Price
$8.76
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Performance Stock Option (right to buy)
Shares / value
2,397,640
Estimated value
Report date
02 Jan 2025
Price
Ownership
By Spouse
Underlying class
Common Stock
Underlying amount
2,397,640
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Stock Option (right to buy)
Shares / value
12,495
Estimated value
Report date
11 Jun 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Affiliated Company 1
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Affiliated Company 2
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

PULSE BIOSCIENCES, INC.

Security class
Warrants (right to buy)
Shares / value
0
Estimated value
Report date
18 Dec 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Co-Chief Executive Officer, Director, 10%+ Owner

Summit Therapeutics Inc.

Security class
Warrant (right to buy)
Shares / value
0
Estimated value
Report date
08 Apr 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Robert W. Duggan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .